BMT CTN Protocol 1201 (Alliance A051301)

A Randomized Double-Blind Phase III Study of Ibrutinib During and Following Autologous Stem Cell Transplantation Versus Placebo in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma of the Activated B-cell Subtype

Below are protocol-related documents, which may be periodically updated.

• Protocol: BMT CTN Protocol 1201 (Alliance A051301)
• This study is posted on clinicaltrials.gov as NCT02443077
• Key Personnel

             Protocol Chair: Charalambos Babis Andreadis, MD, MSCE:              Charalambos.Andreadis@ucsf.edu

             BMT CTN Protocol Chair: Timothy Fenske, MD: tfenske@mcw.edu

             Protocol Coordinator: Amy Foley: afoley@nmdp.org

        

           

For the Alliance A051301/BMT CTN 1201 study, centers participate via their NCTN group. The protocol may be accessed through the CTSU website: https://www.ctsu.org. For questions, contact the CTSU Help Desk: ctsucontact@westat.com or 1-888-823-5923.